12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Company News  |  Deals

Action Pharma, Zealand Pharma, Abbott deal

Abbott will acquire AP214 and related IP from Action Pharma for $110 million in cash. Last year, AP214 met the primary endpoint in a Phase IIb trial to prevent post-surgical kidney injury following cardiac surgery with cardiopulmonary bypass. Abbott plans to start a...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >